Get the Stockscreener App
3.93
4.84%
-0.20
After Hours:
3.87
-0.06
-1.53%
Voyager Therapeutics Inc stock is traded at $3.93, with a volume of 647.67K.
It is down -4.84% in the last 24 hours and up +11.02% over the past month.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$4.13
Open:
$4.05
24h Volume:
647.67K
Relative Volume:
1.21
Market Cap:
$218.51M
Revenue:
$163.78M
Net Income/Loss:
$25.88M
P/E Ratio:
6.0462
EPS:
0.65
Net Cash Flow:
$-28.66M
1W Performance:
-7.09%
1M Performance:
+11.02%
6M Performance:
-7.31%
1Y Performance:
-5.30%
1-Day Range:
$3.84
$4.10
1-Week Range:
$3.84
$4.35
52-Week Range:
$2.645
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.93 | 229.63M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday - MarketBeat
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028 - MarketBeat
Will Voyager Therapeutics Inc. stock gain from lower inflationTrade Analysis Report & Daily Oversold Stock Bounce Ideas - mfd.ru
Voyager Therapeutics at Oppenheimer Conference: Strategic Insights on Alzheimer’s By Investing.com - Investing.com Canada
Voyager Therapeutics (NASDAQ:VYGR) COO Robin Swartz Sells 6,458 Shares - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) CFO Sells $17,598.36 in Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) CEO Alfred Sandrock Sells 14,197 Shares - MarketBeat
Robin Swartz, Voyager Therapeutics COO, sells $24k in VYGR stock - Investing.com Canada
Alfred Sandrock, Voyager Therapeutics CEO, sells $53806 in stock By Investing.com - Investing.com Canada
Voyager Therapeutics CFO sells $17,598 in stock By Investing.com - Investing.com Canada
VYGR | Voyager Therapeutics, Inc. Common FinancialsIncome Statement - Quiver Quantitative
Voyager Therapeutics (VYGR) CFO executes 4,668-share tax sell-to-cover trade - Stock Titan
Voyager Therapeutics (VYGR) CSO auto-sells shares for tax bill - Stock Titan
Earnings Miss: How does Voyager Therapeutics Inc compare to its peersGlobal Markets & Accurate Buy Signal Notifications - baoquankhu1.vn
ARMISTICE CAPITAL, LLC Reduces Stake in Voyager Therapeutics Inc. - GuruFocus
4,174-Share Rule 144 Notice for Voyager Therapeutics (NASDAQ: VYGR) - Stock Titan
VYGR (NASDAQ: VYGR) Rule 144 notice: 6,458 shares tied to vesting - Stock Titan
14,197 shares vest; director sold 12,192 and 11,732 (VYGR) - Stock Titan
VYGR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Voyager Therapeutics (NASDAQ:VYGR) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
[Form 4] Voyager Therapeutics, Inc. Insider Trading Activity - Stock Titan
Is Voyager Therapeutics Inc. stock a smart retirement pickEarnings Overview Report & Daily Market Momentum Tracking - mfd.ru
Tax-driven sale: Voyager (NASDAQ: VYGR) CSO sells 3,301 shares - Stock Titan
Voyager Therapeutics (VYGR) Form 144: 3,301-share proposed sale; insider sold 3,525 - Stock Titan
Alfred W. Sandrock Jr sells 12,192 shares — Voyager (NASDAQ: VYGR) - Stock Titan
EcoR1 discloses 6.8% Voyager Therapeutics (VYGR) ownership stake - Stock Titan
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-02-14 07:15:36 - mfd.ru
Voyager Therapeutics Announces Chief Medical Officer Resignation - The Globe and Mail
What analyst consensus says on Voyager Therapeutics Inc. stockDividend Hike & Target Return Focused Picks - mfd.ru
Is Voyager Therapeutics Inc. subject to activist investor interestWeekly Investment Summary & Daily Chart Pattern Signals - mfd.ru
Todd Alfred Carter Sells 3,525 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) COO Sells $17,590.65 in Stock - MarketBeat
Earnings Miss: Can Voyager Therapeutics Inc reach all time highs this year2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Alfred Sandrock Sells 12,192 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
Form 4: Swartz Robin reports sale transactions in VYGR - Stock Titan
What’s the MACD signal for Voyager Therapeutics Inc.2025 Pullback Review & Weekly High Potential Stock Alerts - mfd.ru
VYGR (NASDAQ: VYGR) holder files to sell 12,192 shares under Rule 144 - Stock Titan
Voyager to Present at Upcoming Investor Conferences - markets.businessinsider.com
FY2030 Earnings Forecast for VYGR Issued By HC Wainwright - MarketBeat
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM) - The Globe and Mail
Can Voyager Therapeutics Inc. continue delivering strong returnsWeekly Stock Recap & Smart Money Movement Tracker - mfd.ru
Weekly Earnings: How does Voyager Therapeutics Inc compare to its peersPortfolio Update Report & Entry Point Confirmation Signals - baoquankhu1.vn
Voyager Therapeutics (NASDAQ:VYGR) Stock Crosses Below Fifty Day Moving AverageWhat's Next? - MarketBeat
Published on: 2026-01-27 16:25:36 - baoquankhu1.vn
Decliners Report: Can Voyager Therapeutics Inc reach all time highs this year - baoquankhu1.vn
Gene Therapy Market Outlook 2026-2031, Featuring Profiles - GlobeNewswire
Gene Therapy Market Outlook 2026-2031, Featuring Profiles of REGENXBIO, Oxford Biomedica, Voyager Therapeutics and More - Yahoo Finance
Stock Market Recap: How does Voyager Therapeutics Inc compare to its peers2025 Trading Volume Trends & Weekly Watchlist of Top Performers - baoquankhu1.vn
Inflation Data: Is Ferroglobe PLC forming a double bottom2025 Biggest Moves & High Return Trade Opportunity Guides - baoquankhu1.vn
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Voyager Therapeutics Inc Stock (VYGR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO |
Feb 24 '26 |
Sale |
3.79 |
14,197 |
53,807 |
484,060 |
| Jorgensen Nathan D. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.77 |
4,668 |
17,598 |
151,416 |
| Carter Todd Alfred | Chief Scientific Officer |
Feb 24 '26 |
Sale |
3.76 |
4,174 |
15,694 |
145,718 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):